Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3004-3011

  Falchook, G S ^a   Moulder, S L ^a   Wheler, J J ^a   Jiang, Y ^a   Bastida, C C ^a   Kurzrock, R ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bevacizumab; Breast cancer; Her2; Lapatinib; Trastuzumab

Indexed keywords

ARRY 380; BEVACIZUMAB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HER2 POSITIVE BREAST CANCER; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN FISSURE; STEREOTACTIC TREATMENT; TREATMENT RESPONSE;

BEVACIZUMAB; BREAST CANCER; HER2; LAPATINIB; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84888816383     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt395     Document Type: Article

References (29)

1. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Prowell TM, Armstrong DK. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?. Semin Oncol 2006; 33: 681-687.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
5. Bhargava R, Gerald WL, Li AR et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18: 1027-1033.
6. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
7. Konecny GE, Meng YG, Untch M et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10: 1706-1716.
8. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
9. Luu T, Chung C, Somlo G. Combining emerging agents in advanced breast cancer. Oncologist 2011; 16: 760-771.
10. Roodink I, Leenders WP. Targeted therapies of cancer: angiogenesis inhibition seems not enough. Cancer Lett 2010; 299: 1-10.
11. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
12. Scaltriti M, Verma C, Guzman M et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumabdependent cell cytotoxicity. Oncogene 2009; 28: 803-814.
13. Xia W, Gerard CM, Liu L et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213-6221.
14. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
15. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379(9816): 633-640.
16. Hurvitz S, Pegram M, Lin L et al. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first-line treatment of HER2-amplified advanced breast cancer. In Thirty-Second Annual Cancer Therapy & Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium 2009. American Association for Cancer Research, San Antonio, TX, 2009.
17. Rugo HS, Franco S, Munster P et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC). In American Society of Clinical Oncology Annual Meeting 2008. American Society of Clinical Oncology, Chicago, IL, 2008.
18. Rugo HS, Jo Chien A, Franco SX et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 134: 13-20.
19. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Hammond ME, Hayes DF, WolffAC. Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011; 29: e458 (17 September 2013, date last accessed).
22. Falchook GS, Wheler JJ, Naing A et al. A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. In American Society of Clinical Oncology Annual Meeting 2010. American Society of Clinical Oncology, Chicago, IL, 2010.
23. Burris HA, III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 9(SUPPL 3): 10-15.
24. Pettinato G, Manivel CJ, Panico L et al. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol 2004; 121: 857-866.
25. Hamilton EP, Blackwell KL. Safety of bevacizumab in patients with metastatic breast cancer. Oncology 2011; 80: 314-325.
26. Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-5261.
27. Jain RK, Lee JJ, Hong D et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010; 16: 1289-1297.
28. Gianni L, Romieu GH, Lichinister M et al. AVEREL: a randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as firstline therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719-1725.
29. Lambrechts D, Lenz HJ, de Haas S et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013; 31: 1219-1230.